TransMedics Group

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade TransMedics Group 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About TMDX

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. 

CEO
Waleed H. Hassanein
CEOWaleed H. Hassanein
Employees
898
Employees898
Headquarters
Andover, Massachusetts
HeadquartersAndover, Massachusetts
Founded
1998
Founded1998
Employees
898
Employees898

TMDX Key Statistics

Market cap
3.40B
Market cap3.40B
Price-Earnings ratio
20.32
Price-Earnings ratio20.32
Dividend yield
Dividend yield
Average volume
1.17M
Average volume1.17M
High today
$102.62
High today$102.62
Low today
$98.48
Low today$98.48
Open price
$101.28
Open price$101.28
Volume
807.78K
Volume807.78K
52 Week high
$156.00
52 Week high$156.00
52 Week low
$62.23
52 Week low$62.23

Stock Snapshot

TransMedics Group(TMDX) stock is priced at $99.38, giving the company a market capitalization of 3.4B. It carries a P/E multiple of 20.32.

On 2026-03-29, TransMedics Group(TMDX) stock traded between a low of $98.48 and a high of $102.62. Shares are currently priced at $99.38, which is +0.9% above the low and -3.2% below the high.

The TransMedics Group(TMDX)'s current trading volume is 807.78K, compared to an average daily volume of 1.17M.

In the last year, TransMedics Group(TMDX) shares hit a 52-week high of $156.00 and a 52-week low of $62.23.

In the last year, TransMedics Group(TMDX) shares hit a 52-week high of $156.00 and a 52-week low of $62.23.

TMDX News

Simply Wall St 2d
TransMedics Group Is Down 13.0% After ENHANCE Heart IDE Approval And Platform Expansion - Has The Bull Case Changed?

Earlier in 2026, TransMedics Group reported US$727–US$757 million in 2026 revenue guidance, a higher operating margin of 13% in the latest quarter, and secured...

TransMedics Group Is Down 13.0% After ENHANCE Heart IDE Approval And Platform Expansion - Has The Bull Case Changed?
Simply Wall St 3d
TransMedics Expands OCS Program As Kidney And Lung Platform Story Grows

TransMedics Group expanded its National Organ Care System Program, aiming to handle a larger share of U.S. transplant procedures. The company is advancing kidn...

TransMedics Expands OCS Program As Kidney And Lung Platform Story Grows

Analyst ratings

82%

of 11 ratings
Buy
81.8%
Hold
18.2%
Sell
0%

People also own

Based on the portfolios of people who own TMDX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.